Your Feed

Filter by
See content from
Back to the latest
Avatar
Henrique
Multiple Myeloma Discussion • January 8, 2025
5 Years in Remission: My Story of Hope
AI-generated title
"I'll never forget the day I received my diagnosis - it was as if my whole world came crashing down. I was 45, healthy, and active, with no family history of cancer. But there it was: Multiple Myeloma. "At first, I felt overwhelmed by the sheer amount of information and treatment options. But I was determined to fight. I started with chemotherapy and stem cell transplantation. The journey was grueling, with countless hospital visits, painful procedures, and debilitating side effects. "Despite the challenges, I remained optimistic, focusing on the little victories along the way. I learned to appreciate the beauty of life's simple moments - a stunning sunset, a warm cup of coffee, or a good book. "Throughout my treatment, I was fortunate to have an incredible support system. My family and friends stood by me, offering love, encouragement, and practical help. My medical team was also exceptional, providing expert care and guidance every step of the way. "It's been five years since my diagnosis, and I'm thrilled to say that I'm in remission. While multiple myeloma will always be a part of my life, I refuse to let it define me. Instead, I've chosen to use my experience to help others, raising awareness and supporting research for this rare and complex disease. "My journey with multiple myeloma has taught me the value of resilience, gratitude, and hope. I've learned to cherish every moment, to appreciate the beauty of life, and to never give up, no matter what challenges come my way."
Avatar
grayDolphin
Multiple Myeloma Discussion • January 8, 2025
Considering Pomalyst for a Stable Low M-Spike?
AI-generated title
MRD testing one year post SCT shows m-spike holding steady at .04. Light chains all normal. Have been on maintenance of 5 mg Rev and Dara injection once a month after SCT. Doc thinking of switching Rev to Pomalyst to try to obliterate m-spike. Not sure about this since still considered in VGPR and with standard risk . Thoughts anyone please?
Avatar
Love
Multiple Myeloma Discussion • January 8, 2025
Celebrating Continued Remission After ASCT
AI-generated title
Happy New Year all I hope this will be encouragement to someone. I was diagnosed in 2017 fall. Started treatment January of 2015 women to a remission in 2018. Saw my oncologist yesterday and I'm still showing no signs of myeloma after stem cell transplant.
Avatar
tim_brinker@sbcglobal.net
Multiple Myeloma Discussion • January 8, 2025
CAR-T After Blenrep & Plasmacytomas: Experiences?
AI-generated title
Hi Myeloma Warriors - Tim here a 14 year myeloma survivor. I have been through a myriad of therapies. One of my longest lasting therapies was Balatamab (Blenrep). I was on Blenrep for 3 1/2 years until my ophthalmologist didn’t approve me to continue, that was March 2024. I have been on no treatment since then, basically waiting for my bloodwork to show active myeloma. In November I started having numbness in my lower back, an MRI identified this as a plasmacytoma in my sacral. I had five days of radiation and began to prepare for CarT. Between November and now another plasmacytoma appeared on my skull, causing headaches and spots have developed on my gallbladder (found on a CT scan last week, had MRI yesterday to further analyze). I start t-cell depletion tomorrow and will receive my T-Cells back next week. I have a few questions: 1. Anyone have success with CarT after being on Blenrep. Now I didn’t fail Blenrep, Blenrep was stopped because of eye impacts. 2. Anyone have success with CarT and plasmacytoma’s and/or extramulldury disease? Thanks, Tim
Avatar
blackBullfrog
Multiple Myeloma Discussion • January 7, 2025
New Drug Approved for Non-SCT Patients
AI-generated title
New drug approved in US for people who aren't good candidates for SCT! https://www.cancer.gov/news-events/cancer-currents-blog/2025/fda-daratumumab-isatuximab-newly-diagnosed-myeloma?cid=eb_govdel And this article ends with, “This is a golden age of treatments for patients with myeloma,” wrote Dr. Stadtmauer. He concluded that most patients with newly diagnosed disease can expect rapid and lasting responses to therapies with tolerable side effects."
Avatar
rubyCrocodile
Multiple Myeloma Discussion • January 7, 2025
Concern About Fluctuating K/L Ratio Post-SCT
AI-generated title
HI, I had SCT in May. I have IGG Kappa. My light chains are staying within range but Kappas are close to the top of the range and fluctuate a lot. The Kappa/lambda ratio is usually 0.80-.90 but lately Lambda is lower than Kappa and ratio is around 1.10. Is that normal? Is it ok for Kappa's to be close to top of the range? It makes me concerned when it reaches near the top of the range.
Avatar
shaila02784@yahoo.com
Multiple Myeloma Discussion • January 7, 2025
Sharing CAR-T Bridging Therapy Experiences?
AI-generated title
Hi, for those who have gone through CAR-T, have you had any bridging therapy before that to bring myeloma under control? Could you please share what treatment you were on as part of the bridging therapy? I have relapsed/became refractory to all the other off the shelf treatments and now my doc is recommending DCEP which I do not want to proceed with and trying to see if there are still other alternatives. Thank you
Avatar
silverLadybug
Multiple Myeloma Discussion • January 7, 2025
Light Chain Test Accuracy and Variability?
AI-generated title
Dear Myeloma Community, Great day, I am 70 years old, diagnosed with Myeloma since almost two years. I am now on Lenalidomide 10mg maintenance dose. I am monitoring the Kappa Light Chains, being my type of disease, as an important marker for progression. I have no m-spike. The outcomes are different from Lab to Lab. Such as I got 129 from one lab and 89 from the other with 1 day difference between giving the blood samples. My question: did anybody come across the question of the accuracy/ tolerance of this test? Is it plus or minus 5%, 10% or? I am not able to judge or find an answer. My doctor says I don't need further tests like a Biopsy or PET, but we need to monitor my condition monthly. Please let me know if you have a similar situation or can help somehow with an advice. Rgds to all
Thumbnail for Allogeneic & Autologous Stem Cell Transplant for Follicular Lymphoma | Yasmina Serroukh, MD | #ASH24
Playlist: ASH 2024

Allogeneic & Autologous Stem Cell Transplant for Follicular Lymphoma | Yasmina Serroukh, MD | #ASH24

Video details & playlist
Thumbnail for Odronextamab as First-Line Therapy in Follicular Lymphoma | Rueme Birhiray, MD | #ASH24
Playlist: ASH 2024

Odronextamab as First-Line Therapy in Follicular Lymphoma | Rueme Birhiray, MD | #ASH24

Video details & playlist
Thumbnail for Phase 3 Asciminib Tolerability Trial , ASC4FIRST,  for Patients with CML | David Andorsky |#ASH2024
Playlist: ASH 2024

Phase 3 Asciminib Tolerability Trial , ASC4FIRST, for Patients with CML | David Andorsky |#ASH2024

Video details & playlist
Thumbnail for The Phase 2 ASC2ESCALATE Trial Evaluating Asciminib for CML Patients | David Andorsky, MD | #ASH2024
Playlist: ASH 2024

The Phase 2 ASC2ESCALATE Trial Evaluating Asciminib for CML Patients | David Andorsky, MD | #ASH2024

Video details & playlist
Thumbnail for Race, Ethnicity, and Socioeconomics Tied to Disparities in Myelofibrosis | Anand Patel, MD | #ASH24
Playlist: ASH 2024

Race, Ethnicity, and Socioeconomics Tied to Disparities in Myelofibrosis | Anand Patel, MD | #ASH24

Video details & playlist
Thumbnail for Fedratinib Helps Myelofibrosis Patients with Low Platelet Counts | Haifa Katrhin Al-Ali, MD | #ASH24
Playlist: ASH 2024

Fedratinib Helps Myelofibrosis Patients with Low Platelet Counts | Haifa Katrhin Al-Ali, MD | #ASH24

Video details & playlist
Thumbnail for BTK Degrader Study Shows Promise for a New Class of CLL Therapies | Alexey Danilov MD PhD | #ASH2024
Playlist: ASH 2024

BTK Degrader Study Shows Promise for a New Class of CLL Therapies | Alexey Danilov MD PhD | #ASH2024

Video details & playlist
Thumbnail for Duration of BTKi therapy correlates with time to next treatment in CLL | Kerry Rogers, MD | #ASH24
Playlist: ASH 2024

Duration of BTKi therapy correlates with time to next treatment in CLL | Kerry Rogers, MD | #ASH24

Video details & playlist